Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Biotechnology

Healthcare
$2.82 -1.97%

-$0.24 today

Market cap
$54.80M
Beta
1.68
P/E (TTM)
-1.1
EPS (TTM)
-$10.75
52W Low $10.03High $69.97

Volume 1.04M

Average 0.49M

Income Statement

Follow revenue through to earnings.

Revenue

$13.11M

FY 2025 · Annual

+29.8% YoY

Operating Income

-$125.70M

FY 2025 · Annual

Net Income

-$124.02M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue007.77M10.09M13.11M
Cost of Revenue004.74M7.77M8.57M
Gross Profit003.03M2.33M4.54M
Gross Margin——39.0%23.1%34.7%
Research & Development68.84M81.88M86.66M40.45M44.49M
Selling, General & Admin23.47M30.22M34.75M40.1M85.76M
Operating Expenses92.31M112.09M121.41M139.03M130.25M
Depreciation & Amortization50K1.25M4.29M3.42M1.93M
EBITDA(92.24M)(108.97M)(112.37M)(74.32M)(122.01M)
EBITDA Margin——-1446.5%-736.3%-930.9%
Operating Income(92.31M)(112.09M)(118.38M)(136.7M)(125.7M)
Operating Margin——-1523.9%-1354.3%-959.1%
Interest Income25K1.87M004.15M
Interest Expense000089K
Other Income / Expenses25K1.87M1.72M6.67M1.68M
Income Before Tax(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Pre-Tax Margin——-1501.8%-1288.3%-946.2%
Income Tax Expense00000
Net Income(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Net Margin——-1501.8%-1288.3%-946.2%
EPS (Basic)(163,968.00)(811.68)(6,368.84)(176.60)(14.57)
EPS (Diluted)(163,968.00)(811.68)(6,368.84)(176.60)(14.57)
Weighted Avg Shares5633.07M1.83M2.26M8.51M
Weighted Avg Shares (Diluted)5633.07M1.83M2.26M8.51M

TNXP Earnings Waterfall · TTM

NASDAQ:TNXP · Revenue to Net Income

Key Ratios

EPS$-14.66
Gross Margin33.7%
Net Margin-960.7%
P/E Ratio-1.5
P/S Ratio62.4

Analysis

$17.6M of revenue converted into -$147.4M of net income for the selected period. Gross margin is 33.7% and net margin is -960.7%, showing how much revenue survives after costs and taxes. EPS is $-14.66, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
8-KCurrent reportNov 13, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026

How much revenue does TNXP generate?

Tonix Pharmaceuticals Holding Corp. (TNXP) reported $13.11M of revenue in fiscal 2025.

Is TNXP profitable?

Tonix Pharmaceuticals Holding Corp. (TNXP) reported -$124.02M of net income, with a net margin of -946.2%.